Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01705353 · ClinicalTrials.gov registry record

The Role of HMGB-1 in Chronic Stroke

A clinical trial, sponsored by Northwell Health.

Terminated
Registry status
39
Enrollment target

NCT01705353: Clinical Trial study, sponsored by Northwell Health.

NCT01705353 is a clinical trial that was terminated before completion, run by Northwell Health. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01705353 was terminated before completion, sponsored by Northwell Health.

TERMINATED
Registry status
39 participants
Enrollment target

Study Summary

The purpose of this study is to measure the presence of HMGB-1 and other proteins in the blood across five time points after stroke, and to determine if their presence correlates with rate of stroke recovery.

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2012-09
Est. Completion 2018-02
Northwell Health

370 total trials

Why NCT01705353 stopped before completion

NCT01705353 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01705353 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01705353 about?

NCT01705353 is a clinical study titled "The Role of HMGB-1 in Chronic Stroke". The purpose of this study is to measure the presence of HMGB-1 and other proteins in the blood across five time points after stroke, and to determine if their presence correlates with rate of stroke recovery.

What is the current status of trial NCT01705353?

This trial is currently terminated. The enrollment target is 39 participants. The study started on 2012-09. Estimated completion is 2018-02.

Who is sponsoring clinical trial NCT01705353?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01705353, the US trial registry maintained by the National Library of Medicine. NCT01705353 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.